Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

The MarketWatch News Department was not involved in the creation of this content. -- Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics' lead ...

CHICAGO -- Retinal injections for eye disease had a significant association with increased complications rates after cataract surgery, according to a large retrospective cohort study. Seven different ...

INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...

New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Scientists reverse eye cell aging with ER-100 gene therapy that reprograms retinal neurons to younger states, offering hope ...

EYLEA HD has shown impressive durable visual improvements and rapid and resilient fluid control with a safety profile comparable to EYLEA Extended dosing intervals with EYLEA HD have the potential to ...

The Global Diabetic Macular Edema Market is experiencing significant growth driven by rising diabetes prevalence and technological advancements in retinal diagnostics like OCT and AI-enabled imaging.